Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.

S M Lee; J A Radford; L Dobson; T Huq; W D Ryder; R Pettengell; G R Morgenstern; J H Scarffe; D Crowther

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.

S M Lee, J A Radford, L Dobson, T Huq, W D Ryder, R Pettengell, G R Morgenstern, J H Scarffe, D Crowther

Research output: Contribution to journal › Article › peer-review

Abstract

In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged less than 60 years with poor-prognosis, high-grade non-Hodgkin's lymphoma (NHL) were entered into a prospective randomized trial between May 1993 and September 1995. Patients were randomized to receive either PBPC alone (n = 12) or PBPC+G-CSF (n = 11) after HDCT with busulphan and cyclophosphamide. G-CSF (300 microg day[-1]) was given from day +5 until recovery of granulocyte count to greater than 1.0 x 10(9) l(-1) for 2 consecutive days. The mean time to achieve a granulocyte count > 0.5 x 10(9) l(-1) was significantly shorter in the G-CSF arm (9.7 vs 13.2 days; P

Original language	English
Journal	British Journal of Cancer
Volume	77
Issue number	8
Publication status	Published - Apr 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Fingerprint

Dive into the research topics of 'Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.'. Together they form a unique fingerprint.

Cite this

Lee, S. M., Radford, J. A., Dobson, L., Huq, T., Ryder, W. D., Pettengell, R., Morgenstern, G. R., Scarffe, J. H., & Crowther, D. (1998). Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. British Journal of Cancer, 77(8).

@article{25f735f7719c43628ad3c591bd965185,

title = "Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.",

abstract = "In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged less than 60 years with poor-prognosis, high-grade non-Hodgkin's lymphoma (NHL) were entered into a prospective randomized trial between May 1993 and September 1995. Patients were randomized to receive either PBPC alone (n = 12) or PBPC+G-CSF (n = 11) after HDCT with busulphan and cyclophosphamide. G-CSF (300 microg day[-1]) was given from day +5 until recovery of granulocyte count to greater than 1.0 x 10(9) l(-1) for 2 consecutive days. The mean time to achieve a granulocyte count > 0.5 x 10(9) l(-1) was significantly shorter in the G-CSF arm (9.7 vs 13.2 days; P",

author = "Lee, {S M} and Radford, {J A} and L Dobson and T Huq and Ryder, {W D} and R Pettengell and Morgenstern, {G R} and Scarffe, {J H} and D Crowther",

year = "1998",

month = apr,

language = "English",

volume = "77",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "8",

}

Lee, SM, Radford, JA, Dobson, L, Huq, T, Ryder, WD, Pettengell, R, Morgenstern, GR, Scarffe, JH & Crowther, D 1998, 'Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.', British Journal of Cancer, vol. 77, no. 8.

Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. / Lee, S M; Radford, J A; Dobson, L et al.
In: British Journal of Cancer, Vol. 77, No. 8, 04.1998.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.

AU - Lee, S M

AU - Radford, J A

AU - Dobson, L

AU - Huq, T

AU - Ryder, W D

AU - Pettengell, R

AU - Morgenstern, G R

AU - Scarffe, J H

AU - Crowther, D

PY - 1998/4

Y1 - 1998/4

N2 - In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged less than 60 years with poor-prognosis, high-grade non-Hodgkin's lymphoma (NHL) were entered into a prospective randomized trial between May 1993 and September 1995. Patients were randomized to receive either PBPC alone (n = 12) or PBPC+G-CSF (n = 11) after HDCT with busulphan and cyclophosphamide. G-CSF (300 microg day[-1]) was given from day +5 until recovery of granulocyte count to greater than 1.0 x 10(9) l(-1) for 2 consecutive days. The mean time to achieve a granulocyte count > 0.5 x 10(9) l(-1) was significantly shorter in the G-CSF arm (9.7 vs 13.2 days; P

AB - In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged less than 60 years with poor-prognosis, high-grade non-Hodgkin's lymphoma (NHL) were entered into a prospective randomized trial between May 1993 and September 1995. Patients were randomized to receive either PBPC alone (n = 12) or PBPC+G-CSF (n = 11) after HDCT with busulphan and cyclophosphamide. G-CSF (300 microg day[-1]) was given from day +5 until recovery of granulocyte count to greater than 1.0 x 10(9) l(-1) for 2 consecutive days. The mean time to achieve a granulocyte count > 0.5 x 10(9) l(-1) was significantly shorter in the G-CSF arm (9.7 vs 13.2 days; P

M3 - Article

C2 - 9579836

SN - 0007-0920

VL - 77

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 8

ER -